Comirnaty receives first authorisation in EU for COVID vaccine in adolescents

Conditional Marketing Authorisation (CMA) for Pfizer and BioNTech’s Comirnaty has been expanded to included individuals 12 to 15 years of age in the EU.

This follows the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) positive opinion to authorize the vaccine in this age group.

The extended indication for the CMA for Comirnaty is valid in all 27 EU member states.

Comirnaty was the first COVID-19 vaccine to receive authorisation in the EU and is the first to have its CMA extended to adolescents.

Distribution and administration by the EU member states will continue to be determined according to the populations identified in the EU and per national guidance.

“Today’s extension of our COVID-19 vaccine authorisation in the European Union is another critical milestone in our collective effort to broaden vaccination programs to as many people as possible,” said Ugur Sahin, CEO and co-founder of BioNTech.

“Making vaccines available  to adolescents will help re-open schools, and support the return to a normal day-to-day life.”

The EU decision is based on data from a pivotal Phase 3 clinical trial, which enrolled 2,260 participants aged 12 to 15 years.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news